Natco Pharma (NSE:NATCOPHARM) Total Liabilities: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:NATCOPHARM Natco Pharma Ltd NSE:NATCOPHARM
87 GF Score
Price ₹841.50
GF Value ₹823.42
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Natco Pharma Total Liabilities?

Natco Pharma NSE:NATCOPHARM -1.44% 87 Total Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:NATCOPHARM with a GF Score™ of 87/100 and a GF Value™ of ₹823.42 (Fairly Valued). The stock has 2 warning signs investors should review.

Natco Pharma's Total Liabilities for the quarter that ended in Jun. 2026 was ₹0 Mil.

Natco Pharma's quarterly Total Liabilities increased from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹18,526.00 Mil) but then declined from Mar. 2026 (₹18,526.00 Mil) to Jun. 2026 (₹0.00 Mil).

Natco Pharma's annual Total Liabilities declined from Mar. 2024 (₹10,532.00 Mil) to Mar. 2025 (₹10,185.00 Mil) but then increased from Mar. 2025 (₹10,185.00 Mil) to Mar. 2026 (₹18,526.00 Mil).

Natco Pharma Total Liabilities Historical Data

* Premium members only.

The historical data trend for Natco Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Natco Pharma Total Liabilities Chart

Natco Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,455.00 7,836.00 10,532.00 10,185.00 18,526.00

Natco Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 17,759.00 0.00 18,526.00 0.00
NSE:NATCOPHARM
87GF Score
Natco Pharma Ltd NSE:NATCOPHARM
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Natco Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Natco Pharma's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=16809+(1042+675
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=18,526

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=110737-92211
=18,526

Natco Pharma's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=N/A

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=N/A-N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ₹0 Mil mean?
Natco Pharma (NSE:NATCOPHARM) has a Total Liabilities of ₹0 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Natco Pharma and its competitors.
Is Natco Pharma's Total Liabilities too high?
Natco Pharma's current Total Liabilities is ₹0 Mil. Overall, Natco Pharma has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Natco Pharma's Total Liabilities compare to ZTS?
Natco Pharma's Total Liabilities of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Natco Pharma and its competitors. Natco Pharma's current Total Liabilities is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natco Pharma stock overvalued right now?
Based on GuruFocus' analysis, Natco Pharma (NSE:NATCOPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹823.42, compared to a current price of ₹841.50 — trading 2.2% above its estimated fair value. The current Total Liabilities is ₹0 Mil. Natco Pharma's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Natco Pharma (NSE:NATCOPHARM), the current Total Liabilities is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Natco Pharma (NSE:NATCOPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Natco Pharma stock appears to be overvalued. The current stock price of ₹841.50 is trading 2.2% above its estimated GF Value™ of ₹823.42. GuruFocus considers Natco Pharma to be Fairly Valued.

Key valuation signals for NSE:NATCOPHARM:

  • Total Liabilities: ₹0 Mil
  • GF Value™: ₹823.42 vs. price of ₹841.50 (2.2% above fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the NSE:NATCOPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Natco Pharma Business Description

Other Exchanges 524816:India
Address Road No. 2, NATCO House, Banjara Hills, Hyderabad, TG, IND, 500034
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
87GF Score

Get the complete analysis for NSE:NATCOPHARM

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹841.50
Price
₹823.42
GF Value